Department of Urology, Uro-Oncology, Robot-assisted and Specialized Urologic Surgery, Cologne University Hospital, Cologne, Germany.
Urol Int. 2022;106(1):20-27. doi: 10.1159/000514041. Epub 2021 May 5.
Symptomatic lymphoceles (SLs) represent the most common complication after radical prostatectomy (RP) and pelvic lymph node dissection (PLND). To date, preoperative risk factors are missing.
Clinical and pathological data of 592 patients who underwent RP and PLND were evaluated. Included parameters were age, BMI, prostate-specific antigen (PSA), PSA ratio, PSA density, number of resected and/or positive lymph nodes, previous abdominal surgery/pelvic radiotherapy, anticoagulation, and surgical approach.
Fifty-nine patients (10%) developed an SL, of which 57 underwent open retropubic radical prostatectomy (RRP) and 2 underwent robot-assisted radical prostatectomy (RARP). Multivariate logistic regression revealed the following parameters as statistically significant risk factors: PSA (odds ratio [OR] = 2.23; 95% CI [1.25; 5.04], p = 0.04), number of resected lymph nodes (OR = 1.47; 95% CI [1.10; 1.97], p < 0.01), previous abdominal surgery (OR = 2.58; 95% CI [1.38; 4.91], p < 0.01), and surgical approach (OR = 0.08; 95% CI [0.01; 0.27], p < 0.01). Previous oral anticoagulation showed almost statistically significant results (OR = 2.39 [0.92; 5.51], p = 0.05).
The risk for SL might be predictable considering preoperative risk factors such as PSA, previous abdominal surgery and anticoagulation. To avoid SL, RARP should be the procedure of choice. If RRP is considered, patients at risk for SL may benefit from peritoneal fenestration during RP.
症状性淋巴囊肿(SLs)是根治性前列腺切除术(RP)和盆腔淋巴结清扫术(PLND)后最常见的并发症。迄今为止,还缺乏术前的危险因素。
对 592 例行 RP 和 PLND 的患者的临床和病理数据进行了评估。纳入的参数包括年龄、BMI、前列腺特异性抗原(PSA)、PSA 比值、PSA 密度、切除和/或阳性淋巴结的数量、既往腹部手术/盆腔放疗、抗凝和手术方式。
59 例(10%)患者发生 SL,其中 57 例行开放式经耻骨后前列腺切除术(RRP),2 例行机器人辅助前列腺切除术(RARP)。多变量逻辑回归显示以下参数为统计学显著的危险因素:PSA(比值比 [OR] = 2.23;95%可信区间 [1.25;5.04],p = 0.04)、切除的淋巴结数量(OR = 1.47;95%可信区间 [1.10;1.97],p < 0.01)、既往腹部手术(OR = 2.58;95%可信区间 [1.38;4.91],p < 0.01)和手术方式(OR = 0.08;95%可信区间 [0.01;0.27],p < 0.01)。既往口服抗凝治疗显示出几乎统计学显著的结果(OR = 2.39 [0.92;5.51],p = 0.05)。
考虑到术前危险因素,如 PSA、既往腹部手术和抗凝治疗,SL 的风险可能是可预测的。为了避免 SL,RARP 应该是首选的手术方式。如果考虑 RRP,有 SL 风险的患者可能会受益于 RP 期间的腹膜开窗术。